Low-Dose Intravenous Ketamine Bolus Versus Conventional Technique
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT03499886 |
|
Recruitment Status : Unknown
Verified April 2018 by Mehdi Nasr Isfahani, Isfahan University of Medical Sciences.
Recruitment status was: Recruiting
First Posted : April 17, 2018
Last Update Posted : April 17, 2018
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Abstract Background: Ketamine has been introduced as one of the most common drugs, administered to sedate children for different painful procedures in the emergency department (ED) but administration in higher dosage causes some severe complications. Thus, the aim of this study was to evaluate the effect of low-dose intravenous ketamine bolus versus conventional injection for reduction of upper and lower extremity fractures in children.
Materials and Methods: In this randomized clinical trial, 198 participants with upper and lower extremity fractures were enrolled. The participants were divided randomly into two groups. In the intervention group, ketamine 1% was administered rapidly at a dose of 0.5 mg / kg (within 5 seconds), and in the control group, ketamine 1.5 mg / kg was slowly injected for 30 to 60 seconds. Then outcomes such as sedation depth and complications were measured for every two minutes and satisfaction of participants and physicians were recorded.
Results: Results showed that the successful sedation rate in the low dose ketamine group was significantly lower, as compared to the control group (7% vs 100%) (p<0.001). Moreover, In terms of duration of drug effect and of recovery, the low dose ketamine group were significantly lower compared with the group receiving higher dosage of ketamine (p<0.05). Furthermore, the sedation depth based on Wisconsin Sedation Scale was significantly higher, in the low dose ketamine group compared to the other group. By evaluating different complications, we found that the rate of neurological (20.4 % vs 5%) and physiological (10.2% vs 2%) complications in the control group was significantly higher compared to the group receiving low-dose ketamine (p<0.05).
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Procedural Sedation | Drug: Ketamine Hydrochloride 50Mg/1mL Solution for Injection Drug: Ketamine Hcl 50Mg/Ml Inj | Phase 2 Phase 3 |
This prospective double-blind clinical trial was conducted in the ED of Isfahan Al-Zahra Hospital, from May 2016 to June 2017. The sedation levels and different outcomes of patients receiving low-dose intravenous ketamine bolus (intervention group) were compared to patients receiving higher doses of intravenous ketamine (control group), for reduction of upper and lower extremity fractures. Inclusion criteria consisted of parents' desire and consent to participate in the study, body mass index (BMI) within the normal range, having age of 6 months to 17 years, requiring a reduction of upper and lower limb fractures, not receiving benzodiazepines and other sedative drugs before intervention.
Exclusion criteria consisted of patients' age <3 months with the body temperature of > 38 ̊C, due to upper respiratory tract infection. Patients having any other complications such as cardiovascular, gastrointestinal, psychological and neurological were excluded from the study. We also excluded the patients who have withdrawn from the study.
Participants and Intervention The study flowchart is shown in figure 1. Two hundreds ten patients with a diagnosis of upper and lower extremity fractures, diagnosed by Emergency Medicine Specialist, were enrolled based on clinical and para-clinical images and inclusion criteria.
The participants were randomly allocated into two groups, using a block randomization procedure with matching subjects in each block based on sex and age. One hundred ninety eight patients completed the study; including one hundred from the intervention group and 98 from the control group. The study received ethics approval from the Ethics Committee of Isfahan University of Medical Sciences (--------------), and all participants and their parents signed the informed consent form.
After obtaining informed consent, eligible patients were enrolled. All patients were monitored by direct observation and continuous cardiovascular monitoring, in order to check the vital signs and also by pulse Oximeters to examine the blood oxygen saturation level.
| Study Type : | Interventional (Clinical Trial) |
| Estimated Enrollment : | 198 participants |
| Allocation: | Randomized |
| Intervention Model: | Parallel Assignment |
| Masking: | Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor) |
| Primary Purpose: | Treatment |
| Official Title: | Low-Dose Intravenous Ketamine Bolus Versus Conventional Technique for Reduction of Upper and Lower Extremity Fractures in Children: A Randomized Controlled Clinical Trial |
| Actual Study Start Date : | January 17, 2017 |
| Estimated Primary Completion Date : | April 28, 2018 |
| Estimated Study Completion Date : | May 14, 2018 |
| Arm | Intervention/treatment |
|---|---|
|
Experimental: Ketamine Hydrochloride 50Mg/1mL
In the intervention group, "Ketamine Hydrochloride 50Mg/1mL" was administered rapidly at a dose of 0.5 mg / kg (within 5 seconds). Patient assessment was performed before and two minutes after ketamine injection, and then every 5 minutes after the reduction of the fracture, by an anesthetist blind to the type of intervention.
|
Drug: Ketamine Hydrochloride 50Mg/1mL Solution for Injection
In the intervention group, ketamine 1% was administered rapidly at a dose of 0.5 mg / kg (within 5 seconds), and in the control group, ketamine 1.5 mg / kg was slowly injected for 30 to 60 seconds.
Other Name: Ketalar |
|
Experimental: Ketamine Hydrochloride 50Mg/mL
in the control group, ketamine 1.5 mg / kg was slowly injected for 30 to 60 seconds. Patient assessment was performed before and two minutes after ketamine injection, and then every 5 minutes after the reduction of the fracture, by an anesthetist blind to the type of intervention.
|
Drug: Ketamine Hcl 50Mg/Ml Inj
In the intervention group, ketamine 1% was administered rapidly at a dose of 0.5 mg / kg (within 5 seconds), and in the control group, ketamine 1.5 mg / kg was slowly injected for 30 to 60 seconds. |
- Sedation depth [ Time Frame: 30 minutes ]By Ramsey sedation scale. With score 1 for restlessness to score 6 for unresponsiveness.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 6 Months to 17 Years (Child) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
- Parents' desire and consent to participate in the study
- Body mass index (BMI) within the normal range
- Having age of 6 months to 17 years
- Requiring a reduction of upper and lower limb fractures.
- Subjects who did not complete study endpoints, however, were included as part on an intention to treat analysis.
Exclusion Criteria:
- Age <6 months
- Body temperature of > 38 ̊C, due to upper respiratory tract infection.
- Participants having any other complications such as cardiovascular, gastrointestinal, psychological and neurological .
- Patients who have withdrawn from the study, or those receiving benzodiazepines and other sedative drugs within 6 hours prior to enrollment.
- Subjects who refused to give consent or those who were judged by investigator as non eligible were excluded as well.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03499886
| Contact: Mehdi Nasr Isfahani, M.D. | +989132034381 | mni.papillon@gmail.com |
| Iran, Islamic Republic of | |
| Al-Zahra University Hospital | Completed |
| Isfahan, Iran, Islamic Republic of, 8138938728 | |
| Mehdi Nasr Isfahani | Recruiting |
| Isfahan, Iran, Islamic Republic of, 8194856781 | |
| Contact: Mehdi Nasr Isfahani m_nasr54@yahoo.com | |
| Contact mni.papillon@gmail.com | |
| Principal Investigator: | Mehdi Nasr Isfahani, M.D. | Isfahan University of Medical Sciences |
| Responsible Party: | Mehdi Nasr Isfahani, Principal Investigator, Isfahan University of Medical Sciences |
| ClinicalTrials.gov Identifier: | NCT03499886 |
| Other Study ID Numbers: |
195027 |
| First Posted: | April 17, 2018 Key Record Dates |
| Last Update Posted: | April 17, 2018 |
| Last Verified: | April 2018 |
| Individual Participant Data (IPD) Sharing Statement: | |
| Plan to Share IPD: | Undecided |
| Studies a U.S. FDA-regulated Drug Product: | No |
| Studies a U.S. FDA-regulated Device Product: | No |
| Product Manufactured in and Exported from the U.S.: | No |
|
Ketamine Analgesics Sensory System Agents Peripheral Nervous System Agents Physiological Effects of Drugs Anesthetics, Dissociative Anesthetics, Intravenous |
Anesthetics, General Anesthetics Central Nervous System Depressants Excitatory Amino Acid Antagonists Excitatory Amino Acid Agents Neurotransmitter Agents Molecular Mechanisms of Pharmacological Action |